uniQure N.V.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $QURE in the last 7 days.
No SEC Form 4 filings for $QURE in the last 30 days.
See all $QURE insider activity →UBS raised its price target for uniQure to $48 from $27 and maintained a buy rating. The stock has seen a 5-day change of 21.98 USD, a 1st Jan change of +4.79%, and a year-to-date change of -8.65%.
uniQure (QURE) shares have fallen 48% in 30 days and 61.41% in 1 year, despite a 3x increase over 3 years. New Phase I/II data showed slowed Huntington's disease progression. Analysts debate if the stock is undervalued at $23.14, with fair value estimates ranging from $62.42 to $353.71, depending on future earnings and FDA approval.
uniQure (QURE) reported Phase I/II data for its Huntington’s disease gene therapy, showing slowed disease progression and a manageable safety profile. The FDA previously indicated that 36-month data could support an accelerated approval BLA. Analysts project significant revenue growth, with consensus estimates at $445.8M and earnings of $20.0M by 2029, though the company remains loss-making. The regulatory decision on the BLA is a key near-term focus for investors.
Recent QURE coverage spans financial news and technology.
UBS raised its price target for uniQure to $48 from $27 and maintained a buy rating. The stock has seen a 5-day change of 21.98 USD, a 1st Jan change of +4.79%, and a year-to-date change of -8.65%.
Positive trial data could lift the stock as it supports potential accelerated approval and revenue growth.
Positive trial data may boost investor confidence and drive the stock higher.
The downgrade and aggressive target reduction suggest immediate downside pressure on QURE.
The downgrade suggests further downside pressure as the trial results weaken the therapeutic outlook.
AlphAI scores every news story that mentions QURE with an AI model for sentiment and relevance, and aggregates insider trades from uniQure N.V.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
UBS raised its price target for uniQure to $48 from $27 and maintained a buy rating. The stock has seen a 5-day change of 21.98 USD, a 1st Jan change of +4.79%, and a year-to-date change of -8.65%.
1 min readuniQure (QURE) shares have fallen 48% in 30 days and 61.41% in 1 year, despite a 3x increase over 3 years. New Phase I/II data showed slowed Huntington's disease progression. Analysts debate if the stock is undervalued at $23.14, with fair value estimates ranging from $62.42 to $353.71, depending on future earnings and FDA approval.
2 min readuniQure (QURE) reported Phase I/II data for its Huntington’s disease gene therapy, showing slowed disease progression and a manageable safety profile. The FDA previously indicated that 36-month data could support an accelerated approval BLA. Analysts project significant revenue growth, with consensus estimates at $445.8M and earnings of $20.0M by 2029, though the company remains loss-making. The regulatory decision on the BLA is a key near-term focus for investors.
3 min readBarclays downgraded uniQure (QURE) from Overweight to Equal-Weight, lowering its price target from $60.00 to $28.00. The company's GF Value™ is $7.94, suggesting it's 195.5% overvalued. uniQure has a GF Score™ of 49/100, indicating mixed financial performance. Analysts cite concerns over financial health and market conditions.
2 min readRBC Capital reduced its price target for uniQure (QURE) to $48 from $65, citing trial data that missed statistical significance. The stock has fallen 39% in a week. Other analysts maintain bullish outlooks with higher targets. uniQure reported a wider-than-expected Q2 loss but revenue beat estimates. The company has FDA agreements for its Huntington’s disease gene therapy, AMT-130.
2 min readuniQure (QURE) shared updated Phase I/II data for AMT-130, showing slowed Huntington’s disease progression. The FDA indicated 36-month high-dose data could support accelerated approval. The company focuses on gene therapies for rare conditions, with AMT-130 as a key catalyst.
2 min readAstraZeneca invested $2B in Summit Therapeutics, boosting its shares 16%. UniQure's stock fell 40% after 4-year trial data for its Huntington's disease therapy showed slower progression than earlier results. The FDA recently approved drugs from AbbVie, Eli Lilly, Merck, and Mirum. Kyverna's CAR T therapy showed positive results for stiff person syndrome, with an FDA submission expected by year-end.
2 min readuniQure (QURE) shares fell 37% after four-year Huntington’s gene therapy study results missed a key test, though three-year data showed significant slowing of disease decline. Analysts maintained bullish ratings, citing strong three-year results and potential FDA approval. The stock closed at $24.51, its worst day since November 2025.
2 min readuniQure reported 48-month data for AMT-130, its gene therapy for Huntington's disease. The study showed a 44% slowing of cUHDRS decline and a 61% slowing on TFC, with the latter reaching statistical significance. The company noted differences in external-control datasets and conducted sensitivity analyses. AMT-130 was generally well-tolerated, with no new serious adverse events. uniQure's BLA submission is based on 36-month data, and the company awaits FDA review.
2 min readuniQure N.V. [QURE] reported that its AMT-130 treatment showed sustained slowing of Huntington's disease progression at 36 and 48 months, with improvements in functional capacity and a favorable safety profile. The company highlighted the stability in Total Functional Capacity (TFC) as clinically meaningful and announced that regulatory submissions are advancing.
1 min read
